Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Advancing gene therapy
for neurodegenerative ophthalmic diseases

We are developing therapies to preserve or restore vision in patients suffering from neurodegenerative retinal diseases
Our mission

Clinical trials

GS010; (lenadogene nolparvovec) is completing its clinical development while GS030 is currently running PIONEER Phase I/II
Check status

Our technologies

  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics
  • View our Technologies
  • Paris
  • New York City
GENSIGHT BIOLOGICS S.A.
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE
Contact us
GENSIGHT BIOLOGICS Inc.
3 East 28th Street
New York, NY 10016
USA
Contact us
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page